Aug 13, 2020
Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis
Jun 19, 2020
Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Jun 18, 2020
RINVOQ(TM) (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
Jun 12, 2020
Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life
Jun 03, 2020
Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis
May 26, 2020
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Apr 03, 2020
Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
Mar 26, 2020
Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36 (difamilast) in Japanese Adult and Pediatric Atopic Dermatitis Patients
Mar 17, 2020
US Dermatologists Anticipate the Future of Atopic Dermatitis to Mirror that of the Over-Crowded Psoriasis Market
Mar 16, 2020
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 16, 2020
Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share
Feb 25, 2020
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
Feb 03, 2020
Atopic Dermatitis (AD) Industry Outlook to 2024 - Elaborate Pipelines of Pharmaceutical Companies Spurs Growth
Jan 29, 2020
Angie Seelal, R-PAC with Advanced Dermatology PC, Shares Tips on Managing Atopic Dermatitis
Jan 27, 2020
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine
Dec 19, 2019
Hoth Therapeutics Enters into Research Collaboration Agreement with Weill Cornell Medicine to Examine the Efficacy of RAMBA in Blocking Acne Pathogenic Gene Expression
Dec 16, 2019
Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in Dogs
Dec 09, 2019
Hoth Therapeutics And North Carolina State University Initiate Preclinical Gene Therapy Study For The Treatment Of Asthma
Dec 07, 2019
Janssen to Acquire Investigational Bermekimab from XBiotech
Nov 07, 2019
Survey Shows People Who First Developed Atopic Dermatitis Symptoms As Kids Experience More Severe Symptoms